Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)

Imaging evaluation was performed every 3 months (± 7 days) from enrollment, and real-time examination was performed if new lesions were suspected. The study was divided into two parts: Part 1: Rexiacin capsules assist in the treatment phase of the TC regimen. Part 2: Rexiacin capsule combined with targeted drug maintenance therapy after the end of chemotherapy. The overall research cycle is roughly divided into screening period, treatment period, and follow-up period: Screening period: -7d\~0d, that is, after the signing of the informed consent form, the screening assessment must be comple

Trial Details

NCT ID

NCT07495397

Phase

NA

Sponsor

The First Hospital of Jilin University

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• Daphne Extract Capsules

Locations (sample)

• Changchun, Jilin, China|43.88,125.32278

Key Eligibility Criteria

• Inclusion Criteria:
• Patients with stage III-IV treatment-naïve ovarian cancer aged 18 to 75 years (including cut-off values) who have completed satisfactory tumor cyto…
• Voluntarily sign the informed consent form;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →